Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Safety and Efficacy of First-Line Nivolumab (NIVO;...
Conference

Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

Authors

Rizvi NA; Gettinger SN; Goldman JW; Hellmann MD; Chow LQ; Juergens R; Borghaei H; Brahmer JR; Shen Y; Harbison C

Volume

10

Pagination

pp. S176-S176

Publisher

ELSEVIER SCIENCE INC

Publication Date

September 1, 2015

Conference proceedings

JOURNAL OF THORACIC ONCOLOGY

Issue

9

ISSN

1556-0864